Known targets — ChEMBL curated mechanism
COXFA4COXFA4L2GPD2MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3
The experimentally established mechanism targets of Metformin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metformin SCHEMBL1547913 | 0.97 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL19583451 | 0.97 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL22977 | 0.97 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL292820 | 0.97 | LMNA (0.35) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL4421557 | 0.97 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL433864 | 0.97 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL15268394 | 0.97 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL18953625 | 0.97 | HTT (0.39) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL1714633 | 0.95 | HTT (0.37) | HTTLMNADPP4ADRA1A | |
| Metformin SCHEMBL28854120 | 0.95 | HTT (0.37) | HTTLMNADPP4ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2384750-A1 | Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid | MARTEK BIOSCIENCES CORPORATION (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110252581-A1 | DEBRIS INHIBITOR FOR SHOES AND METHODS FOR MAKING SAME | TNG Enterprises LLC | 2011-10-20 | — | — | US | disclosed |
| US-20070264331-A1 | Stable pharmaceutical composition of immediate-release glimepiride and extended-release metformin | LABORATORIOS SILANES, S.A DE C.V. (MX) | 2007-11-15 | — | — | US | disclosed |
| EP-1558237-A4 | IMPROVED GLYCEMIC CONTROL FOR PREDIABETES AND/OR DIABETES TYPE II USING DOCOSAHEXAENOIC ACID | MARTEK BIOSCIENCES CORP (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1558237-A2 | IMPROVED GLYCEMIC CONTROL FOR PREDIABETES AND/OR DIABETES TYPE II USING DOCOSAHEXAENOIC ACID | MARTEK BIOSCIENCES CORPORATION (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040092590-A1 | Glycemic control for prediabetes and/or diabetes Type II using docosahexaenoic acid | MARTEK BIOSCIENCES CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004028469-A2 | DOCOHEXAENOIC ACID FOR IMPROVED GLYCEMIC CONTROL | MARTEK BIOSCIENCES CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |